Pittsburgh, PA. May 4th, 2022
We are excited to announce the strategic re-structuring of BioHybrid Solutions, LLC (BHS, LLC). BHS, LLC is now a wholly-owned subsidiary of BioHybrid Solutions Holdings, Inc. (BHSH, Inc.). On the heels of this re-structuring, another wholly-owned subsidiary of BHSH, Inc., BHS Biotechnology, LLC, has been formed.
The success of BHS’s NanoArmoring™ technology platform is the catalyst for this change. Specifically, the deployment of BHS’s capabilities expands the therapeutic window for biological drugs. BHS’s efficient NanoArmoring™ technology addresses the key limitations of commercial biologics drug development: half-life extension, immunogenicity, targeting, and delivery. Armed with best-in-class experience using Atom Transfer Radical Polymerization (ATRP), a comprehensive Intellectual Property portfolio, and a validated technology platform in the biologics arena, BHS Biotechnology is poised to produce numerous safer, needed and otherwise unavailable biological drugs, thereby saving lives.
Simultaneously with the corporate re-structure, Jean Pineault, formerly President & CEO of BHS, LLC, has been appointed as the President & CEO of BHSH, Inc. A new Board of Directors was formed with two non-executive Directors (David Colaizzi, Chair, and Krzysztof Matyjaszewski, CSO), and one executive Director (Jean Pineault).
“BHS is in an envious position with its technology and know-how. As biologics drug development gains speed, it is facing common issues that lead to either termination of too many drug development programs, or only a limited patient population benefit. Some partial solutions have been used to extend half-life, curb immunogenicity, improve targeting, and delivery, but very few provide simultaneous solutions to multiple issues. For example, BHS’s drug development programs have increased half-life over 100 fold, while retaining almost full function, and dramatically reduced immunogenicity. BHS’s re-structuring will be the pivot point from which a series of NanoArmored™ biological therapeutics evolve.” said Pineault.
Based on a step-by-step approach starting with state-of-the-art computerized protein-polymer in silico engineering, the intelligent creation of targeted bioconjugates libraries, and the associated characterization of the candidates, BHS is laying down a decidedly more efficient path for high-throughput biologics problem-solving.
“A big driver of our excitement is being part of the growing Pittsburgh biotech economy – evolving science initiated locally at CMU, establishing an advanced research/manufacturing facility in the community, and developing a talented workforce determined to improve outcomes of therapeutics. We are thankful to benefit from and eager to add to the infrastructure.”, said Colaizzi.
About BioHybrid Solutions Holdings, Inc.
BioHybrid Solutions Holdings Inc. (BHSH, Inc.), has a validated transformational platform technology that develops next-generation NanoArmored™ biological molecules-polymer conjugates. Using proprietary technology originally developed at Carnegie Mellon University, biological molecules are rationally and precisely modified with polymers to dramatically improve their stability and performance. NanoArmor™ technology can dramatically improve processes, resulting in higher throughput and lower costs. The NanoArmor™ platform technology can be applied across the $150 billion+ therapeutics marketplace. In addition, this technology can also open new routes of administration (such as injectable to oral), improve pharmacokinetics, and reduce immunogenicity. BHS is developing the foundation through which any biotherapeutic can be NanoArmored™ to provide cost-effective solutions across industries. Visit us at www.biohybridsolutions.com to learn more.
Please direct your inquiries to:
Megan Kemmerer: email@example.com
More Company News
Technology that could help create paint that can alert people to the presence of a toxin or packaging that changes color with the expiration date of the food inside clearly has potential on the commercial market. And now two long-time collaborators...
Biohybrid Solutions™ is pioneering a new approach to bioconjugate production using polymer-based protein engineering. This innovation allows more control, expands the available polymer library, and minimizes the issues inherent with attaching...